Approaches for Minimizing Metabolic Activation of New Drug Candidates in Drug Discovery
Authors:
- Sanjeev KumarSKSanjeev Kumar
- Kaushik MitraKMKaushik Mitra
- Kelem KassahunKKKelem Kassahun
- Thomas A. BaillieTBThomas A. Baillie
- 21 September 2009
- book chapter
- Published by Springer Nature
- No. 196,p. 511-544
Abstract
A large body of circumstantial evidence suggests that metabolic activation of drug candidates to chemically reactive electrophilic metabolites that are capable of covalently modifying cellular macromolecules may result in acute and/or immune system-mediated idiosyncratic toxicities in humans. Thus, minimizing the potential for metabolic activation of new drug candidates during the drug discovery and lead optimization stage represents a prudent strategy to help discover and develop the next generation of safe and effective therapeutic agents. In the present chapter, we discuss the scientific methodologies that currently are available to industrial pharmaceutical scientists for assessing and minimizing metabolic activation during drug discovery, their attributes and limitations, and future scientific directions that have the potential to help advance progress in this field. We also propose a roadmap that should help utilize the armamentarium of available scientific tools in a logical way and contribute to addressing metabolic activation issues in the drug discovery-setting in a rapid, scientifically appropriate, and resource-conscious manner.Keywords
This publication has 100 references indexed in Scilit:
- Metabolism and Toxicity of Drugs. Two Decades of Progress in Industrial Drug MetabolismChemical Research in Toxicology, 2007
- Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− miceNature Biotechnology, 2007
- Trends in the development of microfluidic cell biochips for in vitro hepatotoxicityToxicology in Vitro, 2007
- MS E with mass defect filtering for in vitro and in vivo metabolite identificationRapid Communications in Mass Spectrometry, 2007
- Bioactivation and Hepatotoxicity of Nitroaromatic DrugsCurrent Drug Metabolism, 2006
- Thiazolidinedione Bioactivation: A Comparison of the Bioactivation Potentials of Troglitazone, Rosiglitazone, and Pioglitazone Using Stable Isotope-Labeled Analogues and Liquid Chromatography Tandem Mass SpectrometryChemical Research in Toxicology, 2006
- Future of ToxicologyMetabolic Activation and Drug Design: Challenges and Opportunities in Chemical ToxicologyChemical Research in Toxicology, 2006
- Estimating The Cost Of New Drug Development: Is It Really $802 Million?Health Affairs, 2006
- Cyanide Trapping of Iminium Ion Reactive Intermediates Followed by Detection and Structure Identification Using Liquid Chromatography−Tandem Mass Spectrometry (LC-MS/MS)Chemical Research in Toxicology, 2005
- Mass spectrometry in the analysis of glutathione conjugatesJournal of Mass Spectrometry, 1993